Novavax Covid-19 vaccine elicits immune response in early trial
Novavax Covid-19 vaccine elicits immune response in early trial
newKerala.com
0 shares
1 views
You might like
Related news coverage
Coronavirus | Oxford COVID vaccine data could go before regulators this year: Director
Hindu
The Oxford vaccine showed early promise in the first human trial when it produced an immune response
-
Covid update: Pfizer says it will have the ability to supply 1.3bn vaccine doses by the end of next year (if trials and approvals go to plan)
Proactive Investors
-
Goldman Sachs lays out 4 themes from 2nd-quarter earnings set to shape the economy's future
Business Insider
-
Pfizer coronavirus vaccine passes early stage trials
Proactive Investors
-
Coronavirus vaccine candidate induces immune response, trial results indicate
Belfast Telegraph
Advertisement
More coverage
Novavax skyrockets 23% after saying its COVID-19 vaccine showed promising results in an early trial (NVAX)
Business Insider
· *On Tuesday, Novavax announced that its COVID-19 vaccine "elicited robust antibody responses" in an early stage clinical..